This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Rena Vassilopoulou-Sellin, MD
University of Texas M. D. Anderson Cancer Center Houston

JAMA. 1993;269(8):991.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.

—As Dr Henrich¹ persuasively points out, there remains no compelling evidence that use of postmenopausal estrogen replacement therapy (ERT) places women at increased risk for the development of breast cancer. While criteria for the rational administration of estrogen are being defined for the general population of postmenopausal women who may benefit from ERT during the latter decades of their lives, guidelines do not exist for the growing number of women who have had the diagnosis of breast cancer at some point before the development of menopause.

Postmenopausal estrogen deficiency places all women, including those who have been treated for breast cancer, at increased risk for osteoporosis and heart disease. However, because of theoretical concerns that estrogen may adversely affect the course of breast cancer, ERT has not been considered appropriate for this latter group of patients.² Thus, an ever-increasing number of young, postmenopausal women with . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?